Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome

Not Applicable

Completed

Conditions: Hyperinsulinism-Hyperammonemia Syndrome

Interventions: Dietary Supplement: Vitamin E

Registration Number: NCT03797222

Lead Sponsor: Elizabeth A Rosenfeld

Brief Summary: Investigators will assess the tolerability of oral Vitamin E supplementation in subjects with congenital hyperinsulinism (HI) and hyperammonemia (HA) syndrome.

Detailed Description: Congenital hyperinsulinism (HI) is a rare disorder of pancreatic beta cell insulin secretion that causes persistent and severe hypoglycemia starting at birth. Hyperinsulinism/hyperammonemia (HI/HA) syndrome is the second most common type of congenital HI and is caused by activating mutations in glutamate dehydrogenase (GDH). Patients with HI/HA exhibit fasting hyperinsulinemic hypoglycemia, protein-induced hypoglycemia, hyperammonemia, seizures, and intellectual disability independent of hypoglycemia. These effects result from abnormal GDH activity in the beta cells, liver and kidney cells, neurons, and astrocytes. The only available treatment for HI/HA syndrome is diazoxide, which acts on the beta cells to decrease insulin secretion but has no effect on GDH activity itself or on other cell types. Thus, there remains a significant unmet need for improved therapies for this disorder. Preliminary data show that Vitamin E (alpha-tocopherol) inhibits GDH activity in cell lines and improves hypoglycemia in a GDH HI mouse model. Based on these preclinical studies, Investigators hypothesize that Vitamin E will inhibit GDH activity and may impact hyperinsulinemic hypoglycemia and hyperammonemia in subjects with HI/HA syndrome. This hypothesis will be tested in a future study. In this initial pilot study, investigators will assess the tolerability of oral Vitamin E supplementation in subjects with HI/HA syndrome.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 14

Inclusion Criteria

Individuals age ≥12 months and ≤40 years
Diagnosis of HI/HA syndrome
On diazoxide therapy for treatment of hypoglycemia
Females ≥11 years of age or menstruating must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
Informed consent for participants ≥18 years. Parental/guardian permission (informed consent) and, if appropriate, child assent for participants <18 years.

Exclusion Criteria

Individuals age <12 months or >40 years
Individuals who have experienced an allergic reaction to Vitamin E
Individuals with a known allergy to dairy, whey, or soy
On concurrent therapy with a medication known to be metabolized by the CYP3A pathway
Individuals with a known increased risk of bleeding (bleeding disorder or on antiplatelet or anticoagulation therapy)
Vitamin E supplementation within 30 days prior to enrollment, including multivitamins containing Vitamin E
Severe hypoglycemia (plasma glucose <50 mg/dL on repeat checks using home glucose meter) more than once weekly within 30 days prior to enrollment.
Evidence of a medical condition that might alter results or compromise the interpretation of results, including active infection, kidney failure, severe liver dysfunction, severe respiratory or cardiac failure.
Evidence of severe hematologic abnormality including severe anemia and/or thrombocytopenia.
Any investigational drug use within 30 days prior to enrollment.
Pregnant or lactating females.
Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Unable to provide informed consent (e.g. impaired cognition or judgment).
Parents/guardians or subjects with limited English proficiency.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vitamin E Supplementation	Vitamin E	Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.

Primary Outcome Measures

Name	Time	Method
Tolerability of Vitamin E Based on Responses to a Subject/Parent-reported Symptom Questionnaire After Vitamin E Supplementation Compared to Baseline	2 weeks	The following symptoms will be scored as either "none" (did not occur)=0, "mild" (minimal symptoms, no treatment needed)=1, "moderate" (symptoms requiring treatment at home or as an outpatient=2, or "severe" (symptoms requiring hospitalization or emergency room visit, or life-threatening or potentially life-threatening symptoms)=4: Seizure, Headache, Vision change/blurred vision, Weakness, Fatigue, Nausea, Vomiting, Diarrhea, Stomach pain, Constipation, Bruising, Bleeding, Rash, Itching, Other Symptom scores will be summed to yield a Tolerability Questionnaire Score for each participant. The Tolerability Questionnaire Score has a minimum score of 0 (symptoms did not occur) and a maximum score of 60 (all of the measured symptoms occurred, each with severe designation). The number (count) of participants with an increase in Tolerability Questionnaire Score from baseline to 2 weeks (following Vitamin E supplementation) will be reported.

Secondary Outcome Measures

Name	Time	Method
Peak Plasma Insulin Concentration	2 weeks	change in peak plasma insulin concentration during oral protein tolerance test following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Plasma Alpha-tocopherol Concentration	2 weeks	change in fasting plasma alpha-tocopherol concentration following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Fasting Plasma Glucose Concentration	2 weeks	change in fasting plasma glucose concentration following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Fasting Plasma Insulin Concentration	2 weeks	change in fasting plasma insulin concentration following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Delta-plasma Glucose Concentration	2 weeks	change in delta-glucose concentration (fasting plasma glucose - nadir plasma glucose during oral protein tolerance test) following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Nadir Plasma Glucose Concentration	2 weeks	change in nadir plasma glucose concentration during oral protein tolerance test following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Delta-plasma Insulin Concentration	2 weeks	change in delta-plasma insulin concentration (peak plasma insulin - fasting plasma insulin during oral protein tolerance test) following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Hypoglycemia Frequency	2 weeks	change in frequency of hypoglycemia (plasma glucose \<70 mg/dL) detected on home glucose meter following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Fasting Plasma Ammonia Concentration	2 weeks	change in fasting plasma ammonia concentration following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])
Delta-plasma Ammonia Concentration	2 weeks	change in delta-plasma ammonia concentration (plasma ammonia at 60 minutes - fasting plasma ammonia during oral protein tolerance test) following Vitamin E supplementation (2 weeks \[visit 2\] - baseline \[visit 1\])